Investing.comDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 19:12:31·⟳ 抓取 19:13:42 +1m11s·⚡ 决策 10-26 19:18:47 +5m05s·1.4 天前
MacroGenics在ESMO 2026公布lorigerlimab II期LINNET中期数据（Investing.com转述，与8分钟前公司通稿同一事件）
search_processed_events命中11:09 UTC（早于本条3分钟、早于抓取4分钟）已处理的同一具体催化：同公司、同药物、同LINNET研究、同ESMO 2026会场、同数据截止日、同全部关键数字（ORR 25% 4/16、DCR 44%、PFS 2.9月、Grade≥3 TRAE 49%、1例5级死亡、24%停药、降至3mg/kg再入组20人、2027H1更新）。本条Investing.com内容明确标注AI生成、编辑审核，系公司新闻稿的二手改写，未新增金额、指引修正、官方新表态或监管进展，属重复消息，按跨源查重规则直接AVOID，不再重复Web/KB/行情/先例研究。
📄 原文Investing.com↗ 原文
MacroGenics reports interim results for lorigerlimab in cancer trial
Five things to watch in markets in the week ahead ROCKVILLE, Md. - MacroGenics Inc. (NASDAQ:MGNX) announced interim res…
不做 MacroGenics Inc.（MGNX.US）
同一ESMO 2026 LINNET中期数据事件已由公司通稿源在11:09 UTC处理并判双向不做；本条为3分钟后Investing.com的AI生成二手转述，无新增事实（弱探索性数据：n=16、ORR 25%、PFS 2.9月、49% Grade≥3 TRAE、1例5级死亡、需降剂量重做、2027H1才更新），无交易级edge，重复消息不再出手
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
本条是MacroGenics ESMO 2026 lorigerlimab LINNET中期数据的Investing.com二手转述，与8分钟前已决策的公司通稿为同一事件且无新增事实；该弱II期探索性数据（n=16、PFS 2.9月、1例死亡、需降剂量重做、2027H1才更新）当时已判双向无交易级edge，重复消息不再交易。
🔎 新鲜度:最早出现 2026-10-26 · 扩散 low · price-in 风险 medium ↗
关键理由
- 数据本身偏弱（CCGC确认ORR仅25%、中位PFS 2.9个月、49% Grade≥3 TRAE、1例5级死亡、24%因不良事件停药），且需降至3mg/kg重新入组、2027H1才更新，无注册或短期收入价值
主要风险
- 若公司随后在ESMO现场给出超出口径的积极指引或分析师上调，可能构成新增事实，但本条转述中不存在
先例如何影响了这次决策
对本次决策的影响:重复消息早停，未重复先例研究；前序同事件决策已覆盖判断
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 251 ms
{"result": "search_processed_events:agent query=`macrogenics esmo 2026 madrid lorigerlimab data | macrogenics lorigerlimab linnet phase 2 clear cell gynecologic cancer interim results esmo 2026 | mgnx lorigerlimab pd-1 ctla-4 bis`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 69.1/72 小时、2729 条本臂决策(完整)，返回 1 条候选。\n• 10-26
原文全文
展开原文 · 2,092 字
Five things to watch in markets in the week ahead
ROCKVILLE, Md. - MacroGenics Inc. (NASDAQ:MGNX) announced interim results from its Phase 2 LINNET study evaluating lorigerlimab in patients with clear cell gynecologic cancer, according to a press release statement issued today.
As of September 1, 2026, the study enrolled 41 patients with advanced gynecologic cancers, including 17 patients with clear cell gynecologic cancer. Among 16 response-evaluable patients with clear cell gynecologic cancer, the confirmed objective response rate was 25%, with four patients responding to treatment. The disease control rate was 44%. All responses remained ongoing at the data cutoff.
The study administered lorigerlimab intravenously every three weeks at 6 mg/kg. Patients with clear cell gynecologic cancer had received a median of one prior line of therapy.
Grade 3 or higher treatment-related adverse events occurred in 49% of patients. The most common events were anemia at 10%, neutrophil count decreased at 10%, and aspartate aminotransferase increased at 7%. Treatment-related adverse events led to discontinuation in 24% of all patients and 18% in clear cell gynecologic cancer patients. One Grade 5 treatment-related adverse event occurred in the platinum-resistant ovarian cancer cohort.
The median progression-free survival in the 17 safety-evaluable patients with clear cell gynecologic cancer was 2.9 months, with a six-month progression-free survival rate of 33%.
MacroGenics is enrolling 20 additional clear cell gynecologic cancer patients at a lower dose of 3 mg/kg every three weeks. The company expects to report updated study results in the first half of 2027.
Lorigerlimab is an investigational bispecific molecule targeting PD-1 and CTLA-4. More than 300 participants have been dosed across all lorigerlimab Phase 1 and Phase 2 clinical trials as of the data cutoff.
The data were presented today at the European Society for Medical Oncology 2026 Congress in Madrid.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ROCKVILLE, Md. - MacroGenics Inc. (NASDAQ:MGNX) announced interim results from its Phase 2 LINNET study evaluating lorigerlimab in patients with clear cell gynecologic cancer, according to a press release statement issued today.
As of September 1, 2026, the study enrolled 41 patients with advanced gynecologic cancers, including 17 patients with clear cell gynecologic cancer. Among 16 response-evaluable patients with clear cell gynecologic cancer, the confirmed objective response rate was 25%, with four patients responding to treatment. The disease control rate was 44%. All responses remained ongoing at the data cutoff.
The study administered lorigerlimab intravenously every three weeks at 6 mg/kg. Patients with clear cell gynecologic cancer had received a median of one prior line of therapy.
Grade 3 or higher treatment-related adverse events occurred in 49% of patients. The most common events were anemia at 10%, neutrophil count decreased at 10%, and aspartate aminotransferase increased at 7%. Treatment-related adverse events led to discontinuation in 24% of all patients and 18% in clear cell gynecologic cancer patients. One Grade 5 treatment-related adverse event occurred in the platinum-resistant ovarian cancer cohort.
The median progression-free survival in the 17 safety-evaluable patients with clear cell gynecologic cancer was 2.9 months, with a six-month progression-free survival rate of 33%.
MacroGenics is enrolling 20 additional clear cell gynecologic cancer patients at a lower dose of 3 mg/kg every three weeks. The company expects to report updated study results in the first half of 2027.
Lorigerlimab is an investigational bispecific molecule targeting PD-1 and CTLA-4. More than 300 participants have been dosed across all lorigerlimab Phase 1 and Phase 2 clinical trials as of the data cutoff.
The data were presented today at the European Society for Medical Oncology 2026 Congress in Madrid.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
a0933499f6· 2026-10-26 19:18 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前